BioSpace News Archive

Business

KalGene Appoints James E. Callaway, Ph.D. as Chief Executive Officer

Veteran Life Sciences Executive Brings Proven Experience Developing CNS Therapeutics

January 4, 2019
·
2 min read
Biotech Beach

NantCell Announces New Celgene Investment

Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th

January 4, 2019
·
14 min read
Biotech Bay

Experience the Smart & Ergonomic Workplace of the Future with Loctek’s Showcase at CES 2019

Loctek will exhibit at CES 2019 in Las Vegas from January 8 to 11, 2019

January 4, 2019
·
3 min read
Business

Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe

Esperion Therapeutics (NASDAQ: ESPR) today announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland.

January 4, 2019
·
8 min read
ASLAN PHARMACEUTICALS ANNOUNCES IND SUBMISSION FOR ASLAN003 TO U.S. FDA AND CONCLUSION OF 30-DAY REVIEW PERIOD

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003.

January 4, 2019
·
5 min read
Drug Development

Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the online publication in SAGE Open Medicine of the results of an investigator-sponsored Phase IIb clinical trial (MSK-001) evaluating Firdapse

January 4, 2019
·
6 min read
Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round – Total Raised CHF35.5 million

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, announces today that it has successfully raised a further CHF15.5 million in an extension of its Series B financing round, announced in January 2018, bringing the total raised to CHF35.5 million

January 4, 2019
·
5 min read
Business

Perseus Holdings USA Appoints Veteran Biotechnology Executive William C. Pearson to Board of Directors

Perseus Holdings USA announced the appointment of William C. Pearson to its board of directors, effective immediately

January 4, 2019
·
5 min read
Business

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk’s SkySTAR™ platform

January 4, 2019
·
6 min read
Deals

LifeX Announces Portfolio Company NeuBase Therapeutics To Merge with Ohr Pharmaceutical

LifeX CEO Dr. Dietrich Stephan to take over as NeuBase Therapeutics CEO; LifeX names University of Pittsburgh’s Dr. Evan Facher as interim CEO

January 4, 2019
·
2 min read